Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01125748 · ClinicalTrials.gov registry record · Phase 4

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

A Phase 4 study of Allergic Asthma, sponsored by Genentech.

Completed
Registry status
Phase 4
Development phase
176
Enrollment target
20
Study locations

NCT01125748 is a Phase 4 study of Allergic Asthma that has completed, run by Genentech. The registered enrollment target is 176 participants, roughly in line with the 162-participant average among 4 other Allergic Asthma trials with a reported enrollment target. The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01125748, a Phase 4 study of Allergic Asthma, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 4
Development phase
176 participants
Enrollment target
20
Study locations

Study Summary

This was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants who completed the EXCELS study (NCT00252135) and had received long-term treatment with Xolair. In addition, participants who did not participate in the EXCELS study but received long-term (\~5 years) treatment with Xolair were allowed to enter the study.

Conditions Studied

Allergic Asthma

Interventions

  • DRUG Placebo
  • DRUG Omalizumab
  • DRUG Asthma therapies

Study Locations (20)

California

  • - Bakersfield
  • - Fresno
  • - Fresno
  • - Granada Hills
  • - Los Angeles
  • - Los Angeles
  • - Napa
  • - Redwood City
  • - Sacramento
  • - San Francisco
  • - San Mateo
  • - Studio City
  • - Walnut Creek

Colorado

  • - Centennial
  • - Thornton

Florida

  • - Bay Pines
  • - Clearwater

Alabama

  • - Huntsville

Arkansas

  • - Little Rock

Connecticut

  • - Waterbury

Trial Details

FieldValue
Enrollment Target 176 participants
Start Date 2010-05
Est. Completion 2013-08
Phase Phase 4

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01125748

The ClinicalTrials.gov registry entry for NCT01125748 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 162-participant average among 4 other Allergic Asthma trials with a reported enrollment target. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Allergic Asthma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01125748 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT01125748 about?

NCT01125748 is a clinical study titled "A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy". This was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants who completed the EXCELS study (NCT00252135) and had received long-term treatment with Xolair. In addition, participants who did not participate in the EXCELS study but received long-term (\~5 years) treatme...

What is the current status of trial NCT01125748?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 176 participants. The study started on 2010-05. Estimated completion is 2013-08.

What conditions does trial NCT01125748 study?

This clinical trial studies the following conditions: Allergic Asthma.

What interventions are being tested in trial NCT01125748?

The interventions under investigation include: Placebo (DRUG), Omalizumab (DRUG), Asthma therapies (DRUG).

Who is sponsoring clinical trial NCT01125748?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01125748 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Allergic Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Allergic Asthma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.